

Viracta Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- [Viracta](#) Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present and host one-on-one meetings at the following upcoming investor conferences:

Credit Suisse 30th Annual Healthcare Conference (virtual)

Conference Dates: November 8 – 12, 2021
Presentation Date: November 11, 2021
Presentation Time: 1:50 PM ET
Format: Corporate presentation

Jefferies London Healthcare Conference (in-person)

Conference Dates: November 16 – 17, 2021
Presentation Date: November 17, 2021
Presentation Time: 10:40 AM GMT/ 5:40 AM ET
Format: Corporate presentation

Piper Sandler 33rd Annual Healthcare Conference (virtual)

Conference Dates: November 29 – December 2, 2021
Presentation: November 22, 2021, at 10:00 AM ET
Available: ET
Format: Corporate presentation

Evercore ISI 4th Annual HealthCONx Conference (virtual)

Conference Dates: November 29 – December 2, 2021
Presentation Date: December 2, 2021
Presentation Time: 3:55 PM ET
Format: Fireside chat

A live webcast of each of the presentations will be available under "Events and Webcasts" in the Investors section of the Viracta website at <https://viracta.investorroom.com/events-and-webcasts>. Replays of each webcast will be archived on the Viracta website for at least 30 days following the presentation.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in two Phase 2 clinical trials for EBV-positive (EBV⁺) lymphoma and one Phase 1b/2 trial in patients with EBV⁺ nasopharyngeal carcinoma and other EBV⁺ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers. For additional information please visit www.viracta.com.

Investor Relations Contact:

Ashleigh Barreto
Head of Investor Relations and Corporate Communications
Viracta Therapeutics, Inc.
abarreto@viracta.com

<https://viracta.investorroom.com/2021-11-01-Viracta-Therapeutics-to-Present-at-Upcoming-Investor-Conferences>